Download PDF
Semin Thromb Hemost
DOI: 10.1055/a-2570-4538
Original Article

Comparison of Platelet Function Tests for Long-Term Cardiovascular Events after Percutaneous Coronary Interventions

Mingyao Zhou   *
1   Department of Cardiology, Changhai Hospital, Shanghai, People's Republic of China
,
Pan Hou   *
1   Department of Cardiology, Changhai Hospital, Shanghai, People's Republic of China
2   Department of Cardiology, General Hospital of the PLA Central Theater Command, Wuhan, People's Republic of China
,
Ying Liang   *
1   Department of Cardiology, Changhai Hospital, Shanghai, People's Republic of China
,
Wenqi Tao   *
3   Department of Cardiology, Jing'an District Centre Hospital of Shanghai, Fudan University, Shanghai, People's Republic of China
,
Zhifu Guo
1   Department of Cardiology, Changhai Hospital, Shanghai, People's Republic of China
,
Bili Zhang
1   Department of Cardiology, Changhai Hospital, Shanghai, People's Republic of China
,
Yang Lu
4   Department of Cardiology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
,
Guojun Chu
5   Department of Cardiology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China
,
Pan Li
1   Department of Cardiology, Changhai Hospital, Shanghai, People's Republic of China
› Author Affiliations Funding The current study was funded by grants from the Shanghai Changhai Hospital “YuanHang Project” and Shanghai Changhai Hospital General Program (2023PY43).
› Further Information
    Permissions and Reprints

Abstract

Patients with high on-treatment platelet reactivity (HTPR) undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) face increased risks of major adverse cardiovascular events (MACEs). Although platelet function tests like thrombelastography (TEG), vasodilator-stimulated phosphoprotein (VASP), PL-11, and VerifyNow have been described, the correlation between them and their prognostic implications remains uncertain. This prospective study aims to evaluate the consistency and effectiveness of four platelet function detection methods in predicting long-term MACEs in patients with ACS. All 98 ACS patients undergoing PCI with clopidogrel were assessed for HTPR using four platelet function detection methods. The endpoint was the occurrence of MACEs, including cardiac death, nonfatal myocardial infarction (MI), and target vessel revascularization (TVR). Among 98 patients enrolled from April 1, 2014 to June 30, 2014, 27 (27.6%) patients with VerifyNow-detected HTPR (P2Y12 reaction units [PRUs] >240). The incidence of HTPR was 58.2% for TEG, 52% for VASP, and 13.3% for PL-11. VerifyNow and TEG showed the highest consistency in detecting HTPR (kappa = 0.201, p = 0.015). During a median follow-up of 6.1 years, 29 MACEs occurred, including 24 TVRs, 3 cardiovascular deaths, and 2 nonfatal MIs. VerifyNow-detected HTPR independently predicted long-term MACEs (hazard ratio: 5.73, 95% confidence interval: 2.04–16.09, p = 0.001), even after adjusting for traditional risk factors (TRFs). Receiver operating characteristic (ROC) analysis indicated that the model incorporating TRFs and VerifyNow-detected HTPR had superior predictive discrimination for MACEs (area under ROC curve = 0.889). VerifyNow-detected HTPR independently emerges as a robust predictor for long-term MACEs, demonstrating superior predictive discrimination compared with other platelet function tests.

Keywords

platelet function tests - major adverse cardiovascular event - VerifyNow - high on-treatment platelet reactivity

Authors' Contributions

P.L., G.J.C., and Y.L. performed the study design. P.H. analyzed data and drafted the manuscript. M.Y.Z., Y.L., and W.Q.T. contributed to the study conception and data collection, analysis, and interpretation. All authors contributed to the revision of the manuscript, read and approved the final manuscript and have participated sufficiently in the work, and agreed to be accountable for all aspects of the work.


Ethics Approval and Consent to Participate

The trial followed the Declaration of Helsinki and had approval from the Institutional Review Board of Changhai Hospital. Each participant provided written informed consent.


* These authors are co-first authors and have contributed equally to this article.




Publication History

Received: 06 January 2025

Accepted: 31 March 2025

Article published online:
25 April 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Sabatine MS, Cannon CP, Gibson CM. et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352 (12) 1179-1189
    CrossrefPubMedSearch in Google Scholar
  • 2 Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol 2018; 72 (23 Pt A): 2915-2931
    PubMedSearch in Google Scholar
  • 3 Collet JP, Thiele H, Barbato E. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42 (14) 1289-1367
    CrossrefPubMedSearch in Google Scholar
  • 4 Duarte JD, Cavallari LH. Pharmacogenetics to guide cardiovascular drug therapy. Nat Rev Cardiol 2021; 18 (09) 649-665
    PubMedSearch in Google Scholar
  • 5 Ma Q, Chen GZ, Zhang YH, Zhang L, Huang LA. Clinical outcomes and predictive model of platelet reactivity to clopidogrel after acute ischemic vascular events. Chin Med J (Engl) 2019; 132 (09) 1053-1062
    PubMedSearch in Google Scholar
  • 6 Parodi G, Marcucci R, Valenti R. et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011; 306 (11) 1215-1223
    CrossrefPubMedSearch in Google Scholar
  • 7 Stone GW, Witzenbichler B, Weisz G. et al; ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382 (9892): 614-623
    PubMedSearch in Google Scholar
  • 8 Sibbing D, Aradi D, Alexopoulos D. et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 2019; 12 (16) 1521-1537
    CrossrefPubMedSearch in Google Scholar
  • 9 Yamani N, Unzek S, Mankani MH. et al. Does individualized guided selection of antiplatelet therapy improve outcomes after percutaneous coronary intervention? A systematic review and meta-analysis. Ann Med Surg (Lond) 2022; 79: 103964
    PubMedSearch in Google Scholar
  • 10 Castrichini M, Luzum JA, Pereira N. Pharmacogenetics of antiplatelet therapy. Annu Rev Pharmacol Toxicol 2023; 63: 211-229
    PubMedSearch in Google Scholar
  • 11 Campo G, Miccoli M, Tebaldi M. et al. Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 2011; 22 (06) 399-407
    PubMedSearch in Google Scholar
  • 12 Sambu N, Curzen N. Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations. Br J Clin Pharmacol 2011; 72 (04) 683-696
    PubMedSearch in Google Scholar
  • 13 Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009; 103 (Suppl. 03) 20A-26A
    Search in Google Scholar
  • 14 Mason GA, Rabbolini DJ. The current role of platelet function testing in clinical practice. Semin Thromb Hemost 2021; 47 (07) 843-854
    Thieme ConnectPubMedSearch in Google Scholar
  • 15 Breet NJ, van Werkum JW, Bouman HJ. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303 (08) 754-762
    CrossrefPubMedSearch in Google Scholar
  • 16 Guan J, Cong Y, Ren J. et al. Comparison between a new platelet count drop method PL-11, light transmission aggregometry, VerifyNow aspirin system and thromboelastography for monitoring short-term aspirin effects in healthy individuals. Platelets 2015; 26 (01) 25-30
    PubMedSearch in Google Scholar
  • 17 Neumann FJ, Sousa-Uva M, Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention 2019; 14 (14) 1435-1534
    CrossrefPubMedSearch in Google Scholar
  • 18 Beattie WS, Wijeysundera DN, Chan MTV. et al; ANZCA Clinical Trials Network for the ENIGMA-II Investigators. Implication of major adverse postoperative events and myocardial injury on disability and survival: a planned subanalysis of the ENIGMA-II trial. Anesth Analg 2018; 127 (05) 1118-1126
    PubMedSearch in Google Scholar
  • 19 Marcucci R, Gori AM, Paniccia R. et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119 (02) 237-242
    PubMedSearch in Google Scholar
  • 20 Pandit N, Rahatekar P, Rekwal L, Kuber D, Nath RK, Aggarwal P. Target vessel versus complete revascularization in non-ST elevation myocardial infarction without cardiogenic shock. Cureus 2022; 14 (03) e23139
    PubMedSearch in Google Scholar
  • 21 Gawaz M, Geisler T, Borst O. Current concepts and novel targets for antiplatelet therapy. Nat Rev Cardiol 2023; 20 (09) 583-599
    CrossrefPubMedSearch in Google Scholar
  • 22 Shao C, Wang J, Tian J, Tang YD. Coronary artery disease: from mechanism to clinical practice. Adv Exp Med Biol 2020; 1177: 1-36
    PubMedSearch in Google Scholar
  • 23 Helten C, Naguib D, Dannenberg L. et al. Platelet function testing: dead or alive. J Thromb Haemost 2018; 16 (05) 984-986
    CrossrefPubMedSearch in Google Scholar
  • 24 Larsen PD, Holley AS, Sasse A, Al-Sinan A, Fairley S, Harding SA. Comparison of Multiplate and VerifyNow platelet function tests in predicting clinical outcome in patients with acute coronary syndromes. Thromb Res 2017; 152: 14-19
    PubMedSearch in Google Scholar
  • 25 Tang XF, Han YL, Zhang JH. et al. Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel. Chin Med J (Engl) 2015; 128 (06) 774-779
    CrossrefPubMedSearch in Google Scholar
  • 26 Xiang Q, Wang Z, Zhang HX. et al. Predicting ischaemic events using platelet reactivity in patients receiving clopidogrel: indirect meta-comparison among VerifyNow, light transmission aggregometry and thromboelastography. Basic Clin Pharmacol Toxicol 2020; 127 (04) 309-319
    PubMedSearch in Google Scholar